Comprehensive Analysis of LPCATs Highlights the Prognostic and Immunological Values of LPCAT1/4 in Hepatocellular Carcinoma

References

• Duran SR, Jaquiss R. Hepatocellular carcinoma. N Engl J Med. 2019;381(1):e2. doi:10.1056/NEJMc1906565
   PubMed Web of Science ®Google Scholar
• Bi J, Ichu TA, Zanca C, et al. Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling. Cell Metab. 2019;30(3):525–538. doi:10.1016/j.cmet.2019.06.014
   PubMed Web of Science ®Google Scholar
• Wang B, Tontonoz P. Phospholipid remodeling in physiology and disease. Annu Rev Physiol. 2019;81:165–188. doi:10.1146/annurev-physiol-020518-114444
   PubMed Web of Science ®Google Scholar
• Sangineto M, Villani R, Cavallone F, et al. Lipid metabolism in development and progression of hepatocellular carcinoma. Cancers (Basel). 2020;12(6):1419. doi:10.3390/cancers12061419
   PubMed Web of Science ®Google Scholar
• Szlasa W, Zendran I, Zalesińska A, et al. Lipid composition of the cancer cell membrane. J Bioenerg Biomembr. 2020;52(5):321–342. doi:10.1007/s10863-020-09846-4
   PubMed Web of Science ®Google Scholar
• Du Y, Wang Q, Zhang X, et al. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):66. doi:10.1186/s13046-017-0525-1
   PubMed Web of Science ®Google Scholar
• Abdelzaher E, Mostafa MF. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence. Tumour Biol. 2015;36(7):5473–5483. doi:10.1007/s13277-015-32148
   PubMedGoogle Scholar
• Grupp K, Sanader S, Sirma H, et al. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Mol Oncol. 2013;7(6):1001–1011. doi:10.1016/j.molonc.2013.07.009
   PubMed Web of Science ®Google Scholar
• Morita Y, Sakaguchi T, Ikegami K, et al. Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. J Hepatol. 2013;59(2):292–299. doi:10.1016/j.jhep.2013.02.030
   PubMed Web of Science ®Google Scholar
• Cotte AK, Aires V, Fredon M, et al. Lysophosphatidylcholine acyltransferase 2 mediated lipid droplet production supports colorectal cancer chemoresistance. Nat Commun. 2018;9(1):322. doi:10.1038/s41467-017-02732-5
   PubMed Web of Science ®Google Scholar
• Wang B, Rong X, Palladino E, et al. Phospholipid remodeling and cholesterol availability regulate intestinal stemness and tumorigenesis. Cell Stem Cell. 2018;22(2):206–220. doi:10.1016/j.stem.2017.12.017
   PubMed Web of Science ®Google Scholar
• Kurabe N, Hayasaka T, Ogawa M, et al. Accumulated phosphatidylcholine (16:0/16:1) in human colorectal cancer; Possible involvement of lpcat4. Cancer Sci. 2013;104(10):1295–1302. doi:10.1111/cas.12221
   PubMed Web of Science ®Google Scholar
• Liu A, Wu Q, Peng D, et al. A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation. Med Res Rev. 2020;40(5):1973–2018. doi:10.1002/med.21696
   PubMed Web of Science ®Google Scholar
• Hu B, Lin JZ, Yang XB, et al. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: a review. Cell Prolif. 2020;53(3):e12772. doi:10.1111/cpr.12772
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180. doi:10.1593/neo.07112
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98- W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352). doi:10.1126/science.aan2507
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1. doi:10.1126/scisignal.2004088
   Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya S, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Györffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123(3):725–731. doi:10.1007/s10549-009-0674-9
   PubMed Web of Science ®Google Scholar
• Ding W, Chen J, Feng G, et al. DNMIVD: DNA methylation interactive visualization database. Nucleic Acids Res. 2020;48(D1):D856–D862. doi:10.1093/nar/gkz830
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhao N, Zhang X, et al. SurvivalMeth: a web server to investigate the effect of DNA methylation-related functional elements on prognosis. Brief Bioinform. 2020;22(3):bbaa162. doi:10.1093/bib/bbaa162
   Web of Science ®Google Scholar
• Modhukur V, Iljasenko T, Metsalu T, et al. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics-UK. 2018;10(3):277–288. doi:10.2217/epi-2017-0118
   PubMed Web of Science ®Google Scholar
• Franz M, Rodriguez H, Lopes C, et al. GeneMANIA update 2018. Nucleic Acids Res. 2018;46(W1):W60–W64. doi:10.1093/nar/gky311
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Pan J, Zhou H, Cooper L, et al. LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. Front Immunol. 2019;10:6. doi:10.3389/fimmu.2019.00006
   PubMed Web of Science ®Google Scholar
• Xiao Z, Hu L, Yang L, et al. TGFβ2 is a prognostic‐related biomarker and correlated with immune infiltrates in gastric cancer. J Cell Mol Med. 2020;24(13):7151–7162. doi:10.1111/jcmm.15164
   PubMed Web of Science ®Google Scholar
• Sceusi EL, Loose DS, Wray CJ. Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford). 2011;13(6):369–376. doi:10.1111/j.1477-2574.2011.00303.x
   PubMed Web of Science ®Google Scholar
• Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971. doi:10.1038/ncomms9971
   PubMed Web of Science ®Google Scholar
• Pope ER, Kimbrough EO, Vemireddy LP, et al. Aberrant lipid metabolism as a therapeutic target in liver cancer. Expert Opin Ther Targets. 2019;23(6):473–483. doi:10.1080/14728222.2019.1615883
   PubMed Web of Science ®Google Scholar
• Swinnen JV, Dehairs J, Talebi A. Membrane lipid remodeling takes center stage in growth factor receptor-driven cancer development. Cell Metab. 2019;30(3):407–408. doi:10.1016/j.cmet.2019.08.016
   PubMed Web of Science ®Google Scholar
• Han C, Yu G, Mao Y, et al. LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production. PLoS One. 2020;15(11):e240801. doi:10.1371/journal.pone.0240801
   Web of Science ®Google Scholar
• Uehara T, Kikuchi H, Miyazaki S, et al. Overexpression of lysophosphatidylcholine acyltransferase 1 and concomitant lipid alterations in gastric cancer. Ann Surg Oncol. 2016;23 Suppl 2:S206–S213. doi:10.1245/s10434-015-4459-6
   PubMed Web of Science ®Google Scholar
• Liu F, Wu Y, Liu J, et al. A miR-205-LPCAT1 axis contributes to proliferation and progression in multiple cancers. Biochem Biophys Res Commun. 2020;527(2):474–480. doi:10.1016/j.bbrc.2020.04.071
   PubMed Web of Science ®Google Scholar
• Wang K, Wu Z, Si Y, et al. Identification of LPCAT1 expression as a potential prognostic biomarker guiding treatment choice in acute myeloid leukemia. Oncol Lett. 2021;21(2):105. doi:10.3892/ol.2020.12366
   PubMed Web of Science ®Google Scholar
• Mansilla F, Da CK, Wang S, et al. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer. J Mol Med (Berl). 2009;87(1):85–97. doi:10.1007/s00109-008-0409-0
   PubMed Web of Science ®Google Scholar
• Zarini S, Hankin JA, Murphy RC, et al. Lysophospholipid acyltransferases and eicosanoid biosynthesis in zebrafish myeloid cells. Prostaglandins Other Lipid Mediat. 2014;113–115:52–61. doi:10.1016/j.prostaglandins.2014.08.003
   PubMed Web of Science ®Google Scholar
• Ye GM, Chen C, Huang S, et al. Cloning and characterization a novel human 1acyl-sn-glycerol-3-phosphate acyltransferase gene AGPAT7. DNA Seq. 2005;16(5):386–390. doi:10.1080/10425170500213712
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Hashidate-Yoshida T, Yamamoto S, et al. Biosynthetic enzymes of membrane glycerophospholipid diversity as therapeutic targets for drug development. Adv Exp Med Biol. 2020;1274:5–27. doi:10.1007/978-3-030-50621-6_2
   PubMed Web of Science ®Google Scholar
• Shindou H, Hishikawa D, Nakanishi H, et al. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J Biol Chem. 2007;282(9):6532–6539. doi:10.1074/jbc.M609641200
   PubMed Web of Science ®Google Scholar
• Taylor LA, Arends J, Hodina AK, et al. Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis. 2007;6:17. doi:10.1186/1476-511X-6-17
   PubMed Web of Science ®Google Scholar
• Abate W, Alrammah H, Kiernan M, et al. Lysophosphatidylcholine acyltransferase 2 (LPCAT2) co-localises with TLR4 and regulates macrophage inflammatory gene expression in response to LPS. Sci Rep. 2020;10(1):10355. doi:10.1038/s41598-020-67000-x
   PubMed Web of Science ®Google Scholar
• Tarui M, Shindou H, Kumagai K, et al. Selective inhibitors of a PAF biosynthetic enzyme lysophosphatidylcholine acyltransferase 2. J Lipid Res. 2014;55(7):1386–1396. doi:10.1194/jlr.M049205
   PubMed Web of Science ®Google Scholar
• Rong X, Albert CJ, Hong C, et al. LXRs regulate er stress and inflammation through dynamic modulation of membrane phospholipid composition. Cell Metab. 2013;18(5):685–697. doi:10.1016/j.cmet.2013.10.002
   PubMed Web of Science ®Google Scholar
• Ishibashi M, Varin A, Filomenko R, et al. Liver X receptor regulates arachidonic acid distribution and eicosanoid release in human macrophages: a key role for lysophosphatidylcholine acyltransferase 3. Arterioscler Thromb Vasc Biol. 2013;33(6):1171–1179. doi:10.1161/ATVBAHA.112.300812
   PubMed Web of Science ®Google Scholar
• Dou L, Ono Y, Chen YF, et al. Hepatic dendritic cells, the tolerogenic liver environment, and liver disease. Semin Liver Dis. 2018;38(2):170–180. doi:10.1055/s-0038-1646949
   PubMed Web of Science ®Google Scholar
• Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017;66(2):342–351. doi:10.1136/gutjnl-2015-310814
   PubMed Web of Science ®Google Scholar
• Endig J, Buitrago-Molina LE, Marhenke S, et al. Dual role of the adaptive immune system in liver injury and hepatocellular carcinoma development. Cancer Cell. 2016;30(2):308–323. doi:10.1016/j.ccell.2016.06.009
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi:10.1038/nri.2017.49
   PubMed Web of Science ®Google Scholar